We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.84%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.13B
AUM Growth
-$201M
Cap. Flow
-$504M
Cap. Flow %
-9.84%
Top 10 Hldgs %
88.73%
Holding
94
New
14
Increased
25
Reduced
6
Closed
34

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$30.9M
2
CELG
Celgene Corp
CELG
+$26.8M
3
BAC icon
Bank of America
BAC
+$13.5M
4
APTV icon
Aptiv
APTV
+$12M
5
C icon
Citigroup
C
+$10.4M

Top Sells

Rank Stock Value
1
LNKD
LinkedIn Corporation
LNKD
+$22.5M
2
YUM icon
Yum! Brands
YUM
+$21.9M
3
MBLY
Mobileye N.V.
MBLY
+$14.8M
4
GM icon
General Motors
GM
+$13.6M
5
V icon
Visa
V
+$13.6M

Sector Composition

Rank Sector Weight
1 Consumer Staples 57.56%
2 Healthcare 18.9%
3 Consumer Discretionary 9.33%
4 Financials 2.31%
5 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
26
Agios Pharmaceuticals
AGIO
$2.08B
$13.6M 0.27%
335,000
+60,000
+22% +$2.57M
BAC icon
27
Bank of America
BAC
$429B
$13.5M 0.26%
+1,000,000
New +$13.5M
MS icon
28
Morgan Stanley
MS
$319B
$12.5M 0.24%
500,000
+200,000
+67% +$5.1M
JPM icon
29
JPMorgan Chase
JPM
$916B
$11.8M 0.23%
200,000
– –
ARRY
30
DELISTED
Array Biopharma Inc
ARRY
$10.9M 0.21%
3,710,000
– –
REGN icon
31
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$10.8M 0.21%
+30,000
New +$12.4M
C icon
32
Citigroup
C
$213B
$10.4M 0.2%
+250,000
New +$10.4M
MET icon
33
MetLife
MET
$62.4B
$10.3M 0.2%
+263,670
New +$9.86M
JUNO
34
DELISTED
Juno Therapeutics, Inc.
JUNO
$10.1M 0.2%
265,000
+75,000
+39% +$2.61M
DAL icon
35
Delta Air Lines
DAL
$56.7B
$9.74M 0.19%
200,000
+100,000
+100% +$4.67M
ALNY icon
36
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
$9.42M 0.18%
+150,000
New +$9.97M
HAPN
37
Happen Inc
HAPN
$2.14B
$9.34M 0.18%
225,000
+10,000
+5% +$420K
AGIO icon
38
CALL
Agios Pharmaceuticals
AGIO
$2.08B
$8.12M 0.16%
200,000
+100,000
+100% +$4.28M
MCRB icon
39
Seres Therapeutics
MCRB
$45M
$5.98M 0.12%
11,250
+2,500
+29% +$1.3M
CLLS
40
Cellectis
CLLS
$288M
$5.78M 0.11%
210,000
– –
SPNC
41
DELISTED
Spectranetics Corp
SPNC
$5.08M 0.1%
350,000
+250,000
+250% +$3.46M
AVXS
42
DELISTED
AveXis, Inc. Common Stock
AVXS
$4.77M 0.09%
+175,000
New +$3.82M
SRPT icon
43
CALL
Sarepta Therapeutics
SRPT
$1.64B
$3.9M 0.08%
200,000
+100,000
+100% +$1.75M
JUNO
44
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.81M 0.07%
+100,000
New +$3.48M
LCTX icon
45
Lineage Cell Therapeutics
LCTX
$264M
$3.68M 0.07%
1,465,383
-123,092
-8% -$275K
RXDX
46
DELISTED
Ignyta, Inc.
RXDX
$3.38M 0.07%
500,000
+25,000
+5% +$206K
PANW icon
47
Palo Alto Networks
PANW
$256B
$3.26M 0.06%
+120,000
New +$2.95M
AGEN
48
Agenus
AGEN
$276M
$3.12M 0.06%
38,212
+10,189
+36% +$687K
CLDX icon
49
Celldex Therapeutics
CLDX
$2.94B
$2.55M 0.05%
45,000
+20,000
+80% +$2.25M
IRWD icon
50
Ironwood Pharmaceuticals
IRWD
$586M
$2.37M 0.05%
258,954
– –
1
2
3 4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2016 Portfolio in Review

As of Q1 2016, Artal Group held 94 positions worth $5.13B, down 3.8% from $5.33B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group withdrew a net $504M in Q1 2016, closing 34 positions and reducing 6 holdings. Its most notable exit was LinkedIn Corporation, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 58% of assets, up from 40% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Goldman Sachs worth $31.4M.

  • Artal Group's largest Q1 2016 buy was Goldman Sachs: 200,000 shares worth $31.4M.
  • Artal Group added most to Celgene Corp in Q1 2016, an estimated $26.8M increase.
  • Artal Group's biggest Q1 2016 reduction was Mastercard, cutting an estimated $8.84M.
  • Artal Group fully exited LinkedIn Corporation in Q1 2016, selling an estimated $22.5M.
  • Artal Group's ten largest holdings make up 89% of its $5.13B portfolio in Q1 2016.
  • Artal Group opened 14 new positions and closed 34 in Q1 2016.
  • Artal Group's portfolio value fell 3.8% quarter-over-quarter to $5.13B.

Based on Artal Group's 13F filing for Q1 2016, filed 12 May 2016.